Clesitamig Biosimilar Trispecific Antibody (DLL3 × CD3 × 4-1BB) for Research

Cat No.: GMP-Bios-INN-1138

Anti-DLL3 therapeutic antibody (Pre-made Clesitamig biosimilar,Bispecific Mixed Domains ((V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa)); Trispecific through dual targetting Fv2) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Clesitamig (development code RO 7616789) is a bispecific antibody targeting DLL3 and CD3. It is developed by Roche for neuroendocrine tumours, small cell lung cancer. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1138-1mg 1mg
GMP-Bios-INN-1138-10mg 10mg
GMP-Bios-INN-1138-100mg 100mg
GMP-Bios-INN-1138-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Clesitamig biosimilar, Bispecific Mixed Domains ((V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa)); Trispecific through dual targetting Fv2, Anti-DLL3;CD3&TNFRSF9/CD137/4-1BB Antibody: Anti-DLL3/Delta-like protein 3/Drosophila Delta homolog 3 (Delta3)/SCDO1 therapeutic antibody
INN Name Clesitamig
Target DLL3;CD3&TNFRSF9/CD137/4-1BB
Format Bispecific Mixed Domains ((V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa)); Trispecific through dual targetting Fv2
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G4;G1
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2024
Year Recommended na
Companies Roche
Conditions Approved na
Conditions Active Neuroendocrine tumours;Small cell lung cancer
Conditions Discontinued na
Production na
Development Tech na